Novo Nordisk (NVO) shares fell 2.1% in early U.S. trading on Tuesday following reports that the company reduced the direct price of Wegovy and Ozempic to $349 per month (with an introductory dose priced at $199). The move comes after an agreement to expand accessibility in the U.S. Meanwhile, Eli Lilly (LLY) also lowered the price of Zepbound, with its shares rising 0.6% in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.